PubMed Health⌕ Search

Biomedical subjects

E Jaeger

Publications and source records attributed to E Jaeger.

At least 73 records · Page 4Linked to original sources
PubMed1975

[Pancreatic response to graded doses of synthetic secretion: comparison between intravenous and pernasal administration in man].

The response of the human pancreas to varying doses of pure synthetic secretin administered intravenously and, for comparison, 8 days later in the form of snuff was examined, intraindividually, in 10 healthy test subjects. After intubation of the stomach and duodenum and continuous instillation of radioactive vitamin B12, the recovery rate of the marker substance was measured in duodenal aspirates and employed to compute the pancreatic bicarbonate and enzyme outputs. The dose-response relationship between pancreatic bicarbonate production and varying doses of synthetic secretin administered intravenously and in the form of snuff, was good. The pancreatic response to a dose of secretin snuff was only about 1/25 of the response obtained with the same dose of secretin injected intravenously. The level of the pancreatic enzyme output remained relatively uninfluenced by varying doses of synthetic secretin.

Administration, Intranasal↗
PubMed1975

Effects of 13-nle-motilin in man--inhibition of gastric evacuation and stimulation of pepsin secretion.

In 3 healthy male volunteers, graded doses of 13-norleucine-motilin (13-nle-motilin)--synthetic analogue of motilin and biologically equivalent to the natural polypeptide--were given intravenously on separate days. Gastric emptying, as determined by means of a radioisotope method, was slowed down dose-dependently by increasing doses of 13-nle-motilin. This was indicated by increasing "half-lives" and "starting indices" of the gastric emptying process, and by decreasing pyloric loss rates, respectively. The gastric pepsin output rose markedly from the basal level during intravenous infusion of 13-nle-motilin.

Adult↗
PubMed1975

Analysis of the motor effects of 13-norleucine motilin on the rabbit, guinea pig, rat, and human alimentary tract in vitro.

Motor effects of 13-norleucine motilin (13-Nle-M), a synthetic analog of motilin and biologically equivalent to the natural polypeptide, on the rabbit, guinea pig, rat, and human alimentary tract were investigated in vitro. Whereas guinea pig and rat preparations proved refractory to 13-Nle-M action, muscle strips of the stomach and upper small intestine from rabbits and man were highly sensitive to 13-Nle-M, contractile responses being elicited with concentrations of less than 2 times 10-minus 9 M. Although circular muscle from rabbit colon responded to 13-Nle-M, Taenia coli preparations were unaffected by the polypeptide; in man, the reverse was observed. Gallbladder, uterine, and vascular smooth muscle were unresponsive to 13-Nle-M. Pharmacological analysis revealed that the effects of 13-Nle-M on the gastrointestinal muscle are not mediated via nervous pathways: ganglion blockade by hexamethonium, blockade of axonal conduction by tetrodotoxin, or anticholinergic action by atropine failed to affect 13-Nle-M actions. It was therefore concluded that 13-Nle-M caused contractions by stimulating receptors on or in the muscle cell. By use of the antihistaminic pheniramine, histamine receptors could be differentiated from the site of 13-Nle-M action. As the contractile response to 13-Nle-M was abolished by the Ca++ antagonistic compound verapamil, a role for 13-Nle-M in the transport of Ca++ to the cytosol of intestinal smooth muscle might be considered.

Acetylcholine↗
PubMed1975

Protein synthesis in human gastric mucosa: effects of pentagastrin, secretin, and 13-nle-motilin.

This study in man (n = 35) deals with the effects of in vivo administration of pentagastrin, synthetic secretin, and 13-norleucine-motilin (13-nle-motillin), respectively, on the in vitro incorporation of 14C-leucine into gastric mucosal protein. From the results presented it may be concluded that pentagastrin has a trophic influence on gastric mucosa in man, too, while protein synthesis in human duodenal mucosa remains unaltered. As the incorporatin of 14C-leucine into gastric mucosal protein is inhibited both by secretion and 13-nle-motiln, it may be hypothesised that secretin and motilin act as functional antagonists of gastrin in the regulation of human gastric mucosal protein synthesis.

Adult↗
PubMed1975

Treatment of duodenal ulcer with a long-acting synthetic secretin: a pilot trial.

In three male duodenal ulcer patients, the effects of a 4-week treatment with a long-acting synthetic secretin -- daily s.c. administrations of 10 clinical units secretin/kg b.w. -- were assessed symptomatically, endoscopically, immunologically, and by means of gastric and pancreatic secretory analyses. Improvement in epigastric pain was noted within a few days following the onset of secretin therapy. In all cases, duodenoscopy revealed complete healing of ulcers after a 2- to 3-week treatment period. Before therapy, cutaneous anaphylactoid reactions due to intradermal injections of secretin could be elicited in each subject; skin reactions were found mitigated after 4 weeks of therapeutic secretin administration thus suggesting some desensitisation. Neither gastric acid secretion nor pancreatic bicarbonate production were substantially influenced by the 4-week course of secretin therapy; consequently, prevention of ulcer relapse is rather unlikely to be achievable with the conditions employed in this study. However, it seems therapeutically promising that the duodenal ulcers under study showed complete healing already after 2-3 weeks of secretin administration.

Adult↗